Neoadjuvant Immunotherapy in Brain Metastases

Neoadjuvant Immunotherapy in Brain Metastases

Publication date: Jun 17, 2020

The purpose of this phase 2 study is to assess the feasibility and efficacy of neoadjuvant immunotherapy in patients with previously untreated, surgically-resectable, solid tumor brain metastases. The primary objectives of this study are to 1) assess the feasibility of neoadjuvant ipilimumab and nivolumab treatment before surgery and stereotactic radiosurgery (SRS) in patients with solid tumor brain metastases as measured by the proportion of patients who have their surgery delayed or surgery never occurs, and 2) demonstrate that neoadjuvant immunotherapy will increase proliferation of circulating T-cells compared to baseline measurements. Exploratory objectives include describing patient progression free survival and overall survival, time to local and distant intracranial progression, the rate of radiation necrosis, and differences in immune expression profiles between patient arms.

Concepts Keywords
ALK MRI
Anaplastic Lymphoma Kinase Radiation
Asymptomatic Lung cancer
Autoimmune Radiation therapy
Barrier Contraception Renal cell carcinoma
Basal Brain metastasis
Birth Control Non-small-cell lung carcinoma
Birth Control Pills Breakthrough therapy
BRAF Antineoplastic drugs
Breast Cancer treatments
Breast Feeding Bristol-Myers Squibb
Carcinoma Health
Cervical Carcinoma Clinical medicine
Condom Vasectomy
Creatinine Immunotherapy
Dexamethasone Barrier contraception
Diaphragm Hysterectomy
EGFR Platelet transfusion
Hemoglobin Birth control
Herniation Stereotactic radiosurgery
Histology Radiation therapy
Homolog Chemo
Hormonal Contraceptives Largest direction metastases
Hypersensitivity Surgically resectable metastases
Hysterectomy Pneumonitis
Immunodeficiency Consent Primary tumor
Immunomodulatory Risks intracranial hemorrhage
Immunosuppressive Active infection
Immunotherapy NSCLC
Infection Sarcoma
Informed Consent Cerebral herniation syndrome
Infusion Tumor brain metastases
Intracranial Hemorrhage
Intrauterine Device
Intravenous
Ipilimumab
IRB
Ligand
Lung
Malignancy
Melanoma
Menopausal
Menses
Metastases
Metastasis
Morbidity
MRI
Murine
Necrosis
Neoadjuvant
Neoplasm
Oncogene
Oophorectomy
Physician
Platelet
Platelet Count
Pneumonitis
Primary Tumor
Radiation
Radiation Therapy
Raf
Renal Carcinoma
Resection
ROS
Sarcoma
Solid Tumor
Spermicide
Squamous
Squamous Carcinoma
Stereotactic Radiosurgery
Surgical Resection
Syndrome
T Cells
Tmax
TNBC
Transfusion
Triple Negative
Tubal Ligation
Vasectomy
Viral
Virus

Semantics

Type Source Name
disease MESH syndrome
drug DRUGBANK Creatinine
disease MESH intracranial hemorrhage
drug DRUGBANK Prothrombin
disease MESH Metastases
disease MESH tumor
drug DRUGBANK Ipilimumab
drug DRUGBANK Nivolumab
disease MESH carcinoma
disease MESH Melanoma
pathway KEGG Melanoma
disease MESH Triple negative breast cancer
drug DRUGBANK Dexamethasone
disease MESH lung disease
disease MESH pneumonitis
disease MESH autoimmune disease
disease MESH hypersensitivity
disease MESH carcinoma in situ
disease MESH heart disease
disease MESH virus infection
disease MESH infection

Original Article

Leave a Comment

Your email address will not be published. Required fields are marked *